Ozempic and Mental Health: A Psychiatrist Separates Signal from Noise
The headlines are alarming. "Ozempic linked to suicidal thoughts." "GLP-1 drugs may cause depression." If you are on semaglutide or thinking about starting, reading those stories probably made your stomach drop.
But headlines are not clinical evidence. Dr. Josef, a practicing psychiatrist, spends over 16 minutes picking apart what we actually know about GLP-1 drugs and mental health. His approach is careful, data-driven, and refreshingly honest about what the research can and cannot tell us right now.
Where the Concern Started
In 2023, the European Medicines Agency (EMA) launched a review after receiving reports of suicidal ideation and self-harm among patients taking GLP-1 receptor agonists. The FDA followed with its own safety review. Media coverage exploded.
Semaglutide went from niche diabetes drug to one of the most prescribed medications in a few years. When millions take any drug, rare adverse events show up in databases. The question is always whether the drug caused the event or it would have happened anyway.
What the Data Actually Shows
The FDA completed its review and found no causal link between GLP-1 medications and suicidal ideation. The EMA reached a similar conclusion. The rates of reported mental health events among semaglutide users were not higher than background rates in the general population with obesity.
That does not mean zero people experienced depression or suicidal thoughts while on the drug. It means the evidence does not support the idea that semaglutide causes these outcomes at a population level. There is no signal in the randomized controlled trial data, which is the strongest evidence we have.
Dr. Josef walks through the STEP trials and SUSTAIN trials specifically, showing that psychiatric adverse events were tracked as endpoints and did not differ significantly between the semaglutide and placebo groups.
But Correlation Is Complicated
Here is where Dr. Josef gets into the nuance that most news coverage misses entirely. Obesity and depression are strongly linked. People with BMIs over 30 have significantly higher rates of depression, anxiety, and suicidal ideation compared to the general population. So the people taking Ozempic are already a higher-risk group for these outcomes.
Rapid weight loss itself can trigger psychological changes. Your relationship with food, your body image, your social identity, and your daily routines all shift when you lose 30, 50, or 80 pounds. Some people experience grief over losing an emotional coping mechanism (food) even as they celebrate the weight loss. That is a real and documented psychological phenomenon.
Caloric restriction also plays a role. Serotonin production depends partly on dietary tryptophan. If you are eating dramatically less, brain chemistry shifts in ways that could affect mood independent of the drug.
Who Is at Higher Risk
Dr. Josef identifies several groups that should be especially attentive to mental health while on GLP-1 therapy. People with a pre-existing history of depression or anxiety. People with a history of eating disorders, particularly binge eating disorder, since GLP-1 drugs change the reward relationship with food. People who are socially isolated, since rapid body changes can be psychologically destabilizing without a support system.
He does not say these people should avoid GLP-1 drugs. He says they should start with a mental health check-in, maintain regular follow-up, and have a low threshold for reaching out if their mood shifts.
The Food-Mood Connection Nobody Talks About
One of the most interesting parts of the video is Dr. Josef's discussion of food as emotional regulation. Many people with obesity use eating as a primary coping mechanism for stress, loneliness, boredom, or anxiety. GLP-1 drugs can fundamentally disrupt the reward pathway that made food a reliable emotional tool.
When that tool is suddenly less effective, some people feel a void. They have lost their primary coping mechanism without developing alternatives. This is where therapy or support groups can make a real difference during GLP-1 treatment.
What the FDA and EMA Reviews Actually Found
The EMA's Pharmacovigilance Risk Assessment Committee reviewed all available data through mid-2024 and concluded that the evidence did not support a causal relationship between GLP-1 drugs and suicidal or self-harming behavior. They recommended updated labeling to mention that reports had been received, standard practice for widely used drugs, but issued no safety warning.
The FDA examined its FAERS database and clinical trial data. The core issue was signal-to-noise: millions were taking these drugs, many with pre-existing depression. Reported mental health event rates did not exceed background rates for a population that size.
One overlooked detail: the STEP and SUSTAIN trials showed modest improvements in quality-of-life scores for semaglutide groups versus placebo. The net mental health effect appears positive on average.
Practical Monitoring Steps If You Are Starting a GLP-1
Dr. Josef's advice on monitoring translates into a few concrete steps you can take starting this week.
Before your first dose, establish a baseline. Rate your mood on a 1-10 scale and note your sleep quality, energy, and any existing anxiety or depressive symptoms. Without a baseline, it is impossible to tell later whether a change is new or was already there.
During the first three months, check in weekly. A simple journal entry about your mood, sleep, and appetite creates a record far more reliable than trying to remember how you felt six weeks ago.
Watch for specific warning signs: persistent sadness lasting more than two weeks, loss of interest in activities you normally enjoy, unexplained sleep disruption, and increased irritability. Any of these warrant a real conversation with your prescriber, more than a passing mention at your next quarterly check-up.
If you have a therapist or psychiatrist, let them know you are starting a GLP-1 drug. If you do not have one and you have a history of depression or anxiety, consider establishing that relationship before starting the medication.
How This Connects to the Addiction Research
Dr. Mike Hansen's video on GLP-1 drugs and addiction covers related territory from the opposite direction. Where Dr. Josef asks whether GLP-1 drugs can cause negative mental health effects, Hansen explores whether they can produce positive ones by reducing compulsive behaviors. Both videos are talking about the same brain circuits, specifically the reward and motivation systems in the nucleus accumbens and prefrontal cortex.
The connection matters because it reframes the mental health question. GLP-1 drugs are not simply "good" or "bad" for your brain. They are modulating a complex reward system that affects appetite, cravings, mood, and motivation simultaneously. For some people, that modulation reduces problematic cravings. For others, it disrupts emotional patterns that were serving a coping function. Same mechanism, different outcomes depending on the individual.
This is why blanket statements like "Ozempic causes depression" or "Ozempic cures addiction" are both too simple. The drug interacts with reward circuitry. What that means for any individual depends on their baseline mental health, their relationship with food, their support systems, and a dozen other factors that no single study can capture.
The Eating Disorder Overlap That Prescribers Need to Screen For
Dr. Josef mentions eating disorders briefly, but this topic deserves more attention because it is one of the highest-risk intersections in GLP-1 therapy. Binge eating disorder (BED) affects an estimated 2-3% of the general population and is significantly more common among people with obesity. Many people seeking GLP-1 medications have undiagnosed BED.
GLP-1 drugs can be genuinely therapeutic for BED. By reducing the reward response to food and suppressing appetite, they can break the binge-restrict cycle that drives the disorder. Some clinicians are already using semaglutide off-label for this purpose with promising results.
But for people with restrictive eating disorders or a history of anorexia, the appetite suppression can reinforce dangerous patterns. A drug that makes it easy to eat 600 calories a day is helpful for someone with BED and harmful for someone with restrictive tendencies. The screening question is simple but often unasked: "Have you ever had periods where you deliberately restricted food to very low levels, and did that feel good or in control?" If the answer is yes, the prescriber needs to factor that into the treatment plan.
If you have any history of disordered eating, bring it up before starting a GLP-1 drug. It does not mean you cannot take it. It means your monitoring plan should include mental health check-ins, more than weight and blood sugar tracking.
Building a Support System Before You Need One
Dr. Josef's advice about monitoring is sound, but it is easier to set up support systems before you start the medication than to scramble for them after a problem appears. Here is a practical approach.
Tell at least one person close to you, a partner, friend, or family member, that you are starting a GLP-1 drug and that mood changes are something to watch for. Give them permission to bring it up if they notice you seem different. People around you often detect mood shifts before you do, especially gradual ones.
If you have a therapist, schedule a session within the first month of starting the medication specifically to check in about the transition. If you do not have a therapist and have any history of depression or anxiety, consider establishing that relationship now. Waiting lists for mental health providers can be weeks or months long, and you do not want to be searching for a therapist while in the middle of a mood crisis.
Online communities for GLP-1 users can provide peer support, but approach them carefully. Some forums are excellent sources of shared experience and practical advice. Others can amplify anxiety with worst-case anecdotes. Look for moderated communities that distinguish between personal experience and medical advice.
What a Good Mental Health Monitoring Protocol Looks Like
Dr. Josef recommends weekly check-ins during the first three months. Here is what that looks like in practice, broken down into something you can do in under five minutes.
Rate three things on a 1-10 scale: overall mood, energy level, and interest in activities you normally enjoy. Write them down in your phone's notes app or a simple journal. The act of rating forces you to actually reflect rather than defaulting to "I'm fine."
Note any of these red flags: sleeping significantly more or less than usual for more than a week, crying more than normal, withdrawing from social activities, persistent irritability that is out of character, or loss of interest in things that usually bring you satisfaction. Any single occurrence is not cause for alarm. A pattern lasting more than two weeks is worth a conversation with your prescriber.
At the three-month mark, compare your current ratings to your baseline. If there is a consistent downward trend that started after beginning the medication, that is data your doctor can work with. If your ratings are stable or improved, you have evidence that the medication is not negatively affecting your mental health, which is reassuring information to have.
The Responsible Take
Dr. Josef's conclusion is nuanced. There is no strong evidence that semaglutide directly causes depression or suicidal ideation. But the experience of being on the drug, losing weight rapidly, and changing your relationship with food can interact with pre-existing vulnerabilities in ways that affect mental health.
The answer is not to avoid GLP-1 drugs out of fear. The answer is to go in with awareness. Talk to your prescriber about your mental health history. Check in with yourself regularly. And if you notice persistent sadness, hopelessness, or thoughts of self-harm, tell someone immediately. That is good advice whether you are on medication or not.